| 2022-05-26 | +65.0% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2022-11-10 | -62.9% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2023-11-16 | +60.8% | legal | SEC EDGAR | APYX 8-K: 5.02 (SEC Filing) |
| 2023-05-11 | +54.3% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2022-03-14 | -42.2% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2024-03-21 | -32.6% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript |
| 2024-03-21 | -32.6% | earnings | Seeking Alpha | Apyx Medical reports mixed Q4 results; initiates FY24 outlook |
| 2024-03-21 | -32.6% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2025-05-13 | +26.8% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2022-08-11 | -25.5% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2025-11-06 | +24.2% | earnings | Seeking Alpha | Apyx Medical outlines $50.5M–$52.5M 2025 revenue target, signals AYON launch momentum |
| 2025-11-06 | +24.2% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q3 2025 Earnings Call Transcript |
| 2025-11-06 | +24.2% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of -$0.05 beats by $0.05, revenue of $12.9M beats by $0.9M |
| 2025-11-06 | +24.2% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2024-11-08 | +20.8% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript |
| 2024-11-08 | +20.8% | news | Seeking Alpha | Apyx Medical looks to raise $7M through direct offering |
| 2024-11-08 | +20.8% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of -$0.14, revenue of $11.5M |
| 2024-11-08 | +20.8% | legal | SEC EDGAR | APYX 8-K: 1.01, 2.02, 2.03, 3.02, 5.02, 8.01 (SEC Filing) |
| 2025-11-07 | +20.7% | news | simplywall.st | Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)? - simplywall.st |
| 2022-01-10 | +18.5% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2021-08-12 | +18.4% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2023-11-28 | -17.7% | legal | SEC EDGAR | APYX 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-11-09 | -16.0% | legal | SEC EDGAR | APYX 8-K: 1.01, 1.02, 2.03 (SEC Filing) |
| 2023-11-09 | -16.0% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2023-08-10 | +15.3% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2022-05-12 | +15.1% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2025-04-29 | +14.9% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2026-03-10 | +14.9% | earnings | Seeking Alpha | Apyx Medical outlines 9%–11% revenue growth target for 2026 as AYON launch accelerates |
| 2026-03-10 | +14.9% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q4 2025 Earnings Call Transcript |
| 2026-03-10 | +14.9% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of -$0.03 beats by $0.03, revenue of $19.16M beats by $0.04M |
| 2026-03-10 | +14.9% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2026-03-10 | +14.9% | news | GlobeNewswire | Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire |
| 2026-03-10 | +14.9% | earnings | Quiver Quantitative | APYX MEDICAL ($APYX) Releases Q4 2025 Earnings - Quiver Quantitative |
| 2026-03-10 | +14.9% | earnings | TradingView | Apyx Medical 2025 10-K: $52.8M Revenue, $(0.27) EPS - TradingView |
| 2023-02-27 | +13.3% | legal | Seeking Alpha | APYX stock gains on FDA nod for Renuvion APR Handpiece in new indication (NASDAQ:APYX) - Seeking Alpha |
| 2025-08-08 | +13.2% | earnings | Seeking Alpha | Apyx Medical outlines $50M–$52M 2025 revenue targets as AYON presales surpass expectations and China launch advances |
| 2025-08-08 | +13.2% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q2 2025 Earnings Call Transcript |
| 2026-03-23 | +12.5% | earnings | Simply Wall St. | How The Apyx Medical (APYX) Story Is Evolving With New Growth Drivers And Profitability Goals |
| 2026-03-23 | +12.5% | news | ChartMill | Gapping stocks in Monday's session - ChartMill |
| 2022-07-18 | +12.4% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2025-05-26 | +12.2% | news | Intellectia AI | APYX Forecast — Price Prediction for 2026. Should I Buy APYX? - Intellectia AI |
| 2024-01-22 | +11.6% | news | Seeking Alpha | Apyx stock rises on publication of Renuvion safety analysis |
| 2024-01-22 | +11.6% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2022-03-21 | -11.5% | legal | SEC EDGAR | APYX 8-K: 5.02 (SEC Filing) |
| 2026-01-12 | +11.2% | earnings | Seeking Alpha | Apyx Medical reports preliminary Q4 revenue up about 34% |
| 2026-01-12 | +11.2% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | +11.2% | earnings | Investing.com | Apyx Medical reports 34% revenue growth in Q4 2025 - Investing.com |
| 2023-03-16 | +10.9% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2021-11-12 | +10.9% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2024-05-09 | +10.4% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of -$0.22 in-line, revenue of $10.2M beats by $0.67M |
| 2024-05-09 | +10.4% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2024-05-09 | +10.4% | legal | SEC EDGAR | APYX 8-K: 1.01, 5.02 (SEC Filing) |
| 2025-01-13 | -10.4% | earnings | Seeking Alpha | Apyx Medical guides Q4 and FY24 revenue above consensus |
| 2025-01-13 | -10.4% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2026-02-03 | -8.4% | news | simplywall.st | Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26% - simplywall.st |
| 2025-10-15 | -8.3% | news | Seeking Alpha | Apyx Medical Corporation (APYX) Virtual KOL Event Transcript |
| 2025-05-11 | -8.0% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q1 2025 Earnings Call Transcript |
| 2025-05-08 | -7.8% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of -$0.10 beats by $0.02, revenue of $9.43M beats by $0.04M |
| 2025-05-08 | -7.8% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2024-01-08 | -7.4% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2025-03-13 | -7.2% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q4 2024 Earnings Call Transcript |
| 2025-03-13 | -7.2% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of -$0.12 beats by $0.04, revenue of $14.22M beats by $0.83M |
| 2025-03-13 | -7.2% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2025-11-19 | +7.2% | legal | SEC EDGAR | APYX 8-K: 1.01, 8.01 (SEC Filing) |
| 2024-10-15 | +6.4% | M&A | Yahoo Finance | Chuck Royce's Strategic Acquisition of Apyx Medical Corp Shares - Yahoo Finance |
| 2025-08-07 | +6.2% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of $0.09 beats by $0.18, revenue of $11.4M misses by $0.3M |
| 2025-08-07 | +6.2% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2026-03-12 | -5.6% | earnings | MarketBeat | Apyx Medical Calls AYON a “Game Changer” at Citizens Conference, Targets Profitability in 2025 |
| 2026-03-12 | -5.6% | expansion | Minichart | Apyx Medical Corporation 2025 Annual Report: Innovation in Surgical Aesthetics, AYON Launch, and Global Expansion - Minichart |
| 2026-01-13 | -5.5% | expansion | RTTNews | Apyx Medical Stock Strengthens On AYON Launch And U.S. Aesthetics Demand - RTTNews |
| 2026-04-13 | -5.2% | news | Cổng thông tin điện tử tỉnh Tây Ninh | What technical signals show for Apyx Medical (APYX) Stock | Price at $3.94, Down 0.51% - High Conviction Picks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2022-03-17 | +4.7% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2024-05-11 | -4.7% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q1 2024 Earnings Call Transcript |
| 2025-02-06 | -4.2% | legal | SEC EDGAR | APYX 8-K: 5.02 and (SEC Filing) |
| 2026-04-10 | -3.9% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Why is Apyx Medical (APYX) Stock moving today | Price at $3.87, Down 3.37% - Top Trending Breakouts - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2022-04-04 | -3.9% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2024-03-04 | -3.7% | news | Stock Titan | Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024 - Stock Titan |
| 2025-01-06 | +3.6% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2026-04-23 | -3.3% | news | GlobeNewswire | Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 |
| 2026-04-23 | -3.3% | earnings | Stock Titan | Apyx Medical schedules May 7 earnings call before market open - Stock Titan |
| 2026-04-23 | -3.3% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | APYX Apyx Medical Corporation posts narrower Q4 2025 loss than analyst estimates, shares climb modestly. - Profit Announcement - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | -3.3% | earnings | Xã Thanh Hà | APYX Apyx Medical Corporation posts narrower Q4 2025 loss than analyst estimates, shares climb modestly. - Revenue Per Share - Xã Thanh Hà |
| 2026-04-21 | -3.1% | earnings | Simply Wall St. | How The Apyx Medical (APYX) Narrative Is Shifting With New Targets Guidance And Growth Drivers |
| 2026-04-21 | -3.1% | news | ChartMill | APYX Stock Price, Quote & Chart | APYX MEDICAL CORP (NASDAQ:APYX) - ChartMill |
| 2024-02-21 | -3.1% | legal | SEC EDGAR | APYX 8-K: 8.01 and (SEC Filing) |
| 2021-08-30 | +3.0% | legal | SEC EDGAR | APYX 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-04-02 | +3.0% | news | Zacks | Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year? |
| 2024-02-22 | -2.6% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2021-05-12 | +2.6% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2026-02-18 | -2.6% | news | GlobeNewswire | Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference - GlobeNewswire |
| 2023-02-24 | +2.4% | legal | SEC EDGAR | APYX 8-K: 1.01, 2.03 (SEC Filing) |
| 2026-03-31 | -2.3% | earnings | Zacks | Tilray Brands' Q3 Earnings on the Horizon: What's in The Offing? |
| 2024-08-11 | +1.9% | earnings | Seeking Alpha | Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript |
| 2023-04-18 | -1.7% | legal | SEC EDGAR | APYX 8-K: 1.01 and (SEC Filing) |
| 2025-11-18 | -1.5% | news | Seeking Alpha | Apyx Medical announces pricing of $10M offering of common stock |
| 2025-11-18 | -1.5% | news | Yahoo Finance | Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock - Yahoo Finance |
| 2026-04-06 | +1.4% | earnings | Simply Wall St. | Why The Apyx Medical (APYX) Story Is Shifting With New Guidance And GLP-1 Demand |
| 2023-03-15 | +1.4% | legal | SEC EDGAR | APYX 8-K: 1.01 and (SEC Filing) |
| 2026-04-20 | -1.2% | analyst | Zacks | Is Agenus (AGEN) Outperforming Other Medical Stocks This Year? |
| 2026-03-17 | +1.1% | analyst | Zacks | Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? |
| 2026-03-17 | +1.1% | M&A | Stock Titan | Apyx Medical (APYX) SVP exercises stock options to acquire 37,000 shares - Stock Titan |
| 2026-03-17 | +1.1% | analyst | Yahoo Finance | Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? - Yahoo Finance |
| 2026-04-01 | -1.1% | news | PR Newswire | Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener" |
| 2026-04-01 | -1.1% | news | Stock Titan | Renuvion wins NewBeauty again, extending its skin-tightening streak - Stock Titan |
| 2026-04-17 | -1.0% | news | Quiver Quantitative | APYX | Apyx Medical Corporation Common Insider Trading - Quiver Quantitative |
| 2026-04-17 | -1.0% | earnings | ChartMill | APYX Earnings History & Surprises | EPS & Revenue Results | APYX MEDICAL CORP (NASDAQ:APYX) - ChartMill |
| 2026-04-18 | -0.8% | earnings | MarketBeat | Apyx Medical (NASDAQ:APYX) Stock Rating Upgraded by Wall Street Zen - MarketBeat |
| 2025-11-17 | -0.5% | news | Seeking Alpha | Apyx Medical announces public offering of common stock; shares down |
| 2024-08-08 | +0.2% | earnings | Seeking Alpha | Apyx Medical GAAP EPS of -$0.19 beats by $0.01, revenue of $12.14M beats by $0.39M |
| 2024-08-08 | +0.2% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |
| 2022-06-13 | +0.1% | legal | SEC EDGAR | APYX 8-K: 8.01 (SEC Filing) |
| 2023-01-10 | +0.1% | legal | SEC EDGAR | APYX 8-K: 2.02 and (SEC Filing) |